Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity Lands $7.5M in Debt Financing

NEW YORK (GenomeWeb) – DxTerity Diagnostics announced on Tuesday that it has arranged to receive up to $7.5 million in term debt financing from SWK Funding, a subsidiary of SWK Holdings.

The firm said it will use the proceeds toward the commercialization of its DxDirect genomics testing platform and DxCollect MicroCollection Device (MCD).

The firm's proprietary chemistry, DxDirect, enables multiplexed genomic testing directly from the patient sample. The DxCollect MCD allows for the stabilization and transport of blood RNA collected from a finger or heel prick.

"This funding allows DxTerity to aggressively pursue the commercialization of its technology, including [the] expansion of DxDirect to next-generation sequencing systems, and [the use of] DxCollect MCD to power direct-to-patient clinical studies for accelerated validation of molecular diagnostic assays," DxTerity CEO Bob Terbrueggen said in a statement.

In February, a partnership between DxTerity and Duke University received $10.4 million from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority to continue developing a genetic test for radiation exposure.



The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.